Used in cancer immunotherapy to enhance the body's immune response against tumors by blocking the CTLA-4 receptor on T-cells, which normally downregulates immune activity. This inhibition promotes T-cell activation and proliferation, enabling the immune system to more effectively recognize and destroy cancer cells. Investigated in clinical trials for various solid tumors, including melanoma and non-small cell lung cancer, often in combination with other checkpoint inhibitors like anti-PD-1/PD-L1 antibodies. Its application aims to improve durable response rates and overall survival in patients with advanced or refractory cancers.